Barrington analyst Michael Petusky raised the firm’s price target on Anika Therapeutics (ANIK) to $16 from $15 and keeps an Outperform rating on the shares. The firm, which continues to think shares are “meaningfully undervalued,” says “it appears that the company agrees” based on its recent decision to commence a $15M 10b5-1 share repurchase that it expects to complete by this June.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIK: